A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

What Was Tested

The trial (phase 3) is built around Tirzepatide and Eloralintide.

Participation in the study will last about 2 years.

It had eight arms (groups): one (experimental), one (experimental), one (experimental), one (experimental) and one (experimental).

Participants will receive EloraTZP subcutaneously (SC).

Participants will receive EloraTZP SC.

Participants will receive EloraTZP SC.

The registry classes the interventions as drug.

Who Took Part

2115 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have a BMI of ≥35 kg/m2 at screening.

The full record lists 3 inclusion and 12 exclusion criteria; among the exclusions: have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening); have type 1 diabetes, type 2 diabetes, or any other type of diabetes; have had within 90 days prior to screening:.

How the Study Was Run

Design: randomized, parallel-group and double-blind.

The participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Neither the participants nor the staff measuring them knew who was on Tirzepatide, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and investigator.

It started in 2026-12 with completion listed for 2029-10.

It ran at 155 sites in United States (55), China (25), Argentina (20), South Korea (13), India (12) and Germany (11).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Percent Change from Baseline in Body Weight (time frame: Baseline, Week 100).

It also tracked 20 secondary outcomes, for example Change from Baseline in Waist Circumference, Percent Change from Baseline in Triglycerides, Change from Baseline in Systolic Blood Pressure, Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP), Percent Change from Baseline in Total Body Fat Mass and Change from Baseline in Body Mass Index (BMI).

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Tirzepatide and Eloralintide in 2115 people.

With 2115 participants it is a large trial for this field.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page and the Eloralintide compound page, all human trials.